Rhianna Rowland Svitlana Korolchuk Dr Marco Salamina Dr Natalie Tatum Professor Martin Noble et al. | Cryo-EM structure of the CDK2-cyclin A-CDC25A complex | 2024 |
|
Dr Celine Cano Professor Jane Endicott Dr Ian Hardcastle Dr Claire Jennings Suzanne Kyle et al. | Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile | 2024 |
|
Rhianna Rowland Dr Richard Heath Professor Jane Endicott Professor Martin Noble Dr Marco Salamina et al. | Cryo-EM structure of SKP1-SKP2-CKS1 in complex with CDK2-cyclin A-p27KIP1 | 2023 |
|
Dr Mathew Martin Professor Jane Endicott Professor Martin Noble Dr Natalie Tatum
| Crystallographic fragment screening in academic cancer drug discovery | 2023 |
|
Svitlana Korolchuk Professor Jane Endicott
| Cyclin A and Cks1 promote kinase consensus switching to non-proline-directed CDK1 phosphorylation | 2023 |
|
Dr Ian Hope Professor Jane Endicott Dr Jessica Watt
| Emerging approaches to CDK inhibitor development, a structural perspective | 2023 |
|
Gemma Davison Dr Mathew Martin Dr Shannon Turberville Selma Dormen Dr Richard Heath et al. | Mapping ligand interactions of bromodomains BRD4 and ATAD2 with FragLites and PepLites ─ Halogenated probes of druglike and peptide-like molecular interactions | 2022 |
|
Duncan Miller Tristan Reuillon Dr Lauren Molyneux Dr Tim Blackburn Dr Noel Edwards et al. | Parallel Optimization of Potency and Pharmacokinetics Leading to the Discovery of a Pyrrole Carboxamide ERK5 Kinase Domain Inhibitor | 2022 |
|
Islam Al-Khawaldeh Dr Christine Basmadjian Dr Cinzia Bordoni Dr Suzannah Harnor Amy Heptinstall et al. | An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK) | 2021 |
|
Dr Marco Salamina Dr Richard Heath Svitlana Korolchuk Dr Arnaud Basle Dr Martyna Pastok et al. | Discriminative SKP2 Interactions with CDK-Cyclin Complexes Support a Cyclin A-Specific Role in p27KIP1 Degradation | 2021 |
|
Dr Natalie Tatum Professor Jane Endicott
| Chatterboxes: the structural and functional diversity of cyclins | 2020 |
|
Daniel Wood Svitlana Korolchuk Dr Natalie Tatum Lan Wang Professor Jane Endicott et al. | Differences in the conformational energy landscape of CDK1 and CDK2 suggest a mechanism for achieving selective CDK inhibition | 2019 |
|
Daniel Wood Daniel Lopez Fernandez Leanne Knight Islam Al-Khawaldeh Dr Conghao Gai et al. | FragLites - minimal, halogenated fragments displaying pharmacophore doublets. An efficient approach to druggability assessment and hit generation | 2019 |
|
Stephanie Myers Duncan Miller Dr Lauren Molyneux Dr Mercedeh Arasta Dr Ruth Bawn et al. | Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38α and BRD4 | 2019 |
|
Duncan Miller Dr Mathew Martin Santosh Adhikari Alfie Brennan Professor Jane Endicott et al. | Identification of a novel ligand for the ATAD2 bromodomain with selectivity over BRD4 through a fragment growing approach | 2018 |
|
Daniel Wood Professor Jane Endicott
| Structural insights into the functional diversity of the CDK–cyclin family | 2018 |
|
Christopher Coxon Dr Suzannah Harnor Dr Mathew Martin Dr Benoit Carbain Emeritus Professor Bernard Golding et al. | Cyclin-Dependent Kinase (CDK) Inhibitors; Structure-Activity Relationships and Insights into the CDK-2 Selectivity of 6-Substituted 2-Arylaminopurines | 2017 |
|
Stephen Hallett Dr Martyna Pastok Dr Anita Wittner Professor Steve Wedge Professor Martin Noble et al. | Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System | 2017 |
|
Dr Mathew Martin Professor Jane Endicott Professor Martin Noble
| Structure-based discovery of cyclin-dependent protein kinase inhibitors | 2017 |
|
Svitlana Korolchuk Dr Mathew Martin Dr Will Stanley Professor Martin Noble Professor Jane Endicott et al. | CDK1 structures reveal conserved and unique features of the essential cell cycle CDK | 2015 |
|
Elisa Meschini Dr Regina Mora Vidal Dr Mathew Martin Dr Will Stanley Tristan Reuillon et al. | Identification and characterization of an irreversible inhibitor of CDK2 | 2015 |
|
Bailey Massa Dr Mathew Martin Professor Martin Noble Professor Jane Endicott
| Structural and functional characterization of Skp2-containing complexes | 2015 |
|
Dr Benoit Carbain Dr Allyson Campbell Dr Celine Cano Professor Jane Endicott Emeritus Professor Bernard Golding et al. | 8-Substituted O-6-Cyclohexylmethylguanine CDK2 Inhibitors: Using Structure-Based Inhibitor Design to Optimize an Alternative Binding Mode | 2014 |
|
Professor Jane Endicott
| A Code for RanGDP Binding in Ankyrin Repeats Defines a Nuclear Import Pathway | 2014 |
|
Dr Alison Hole Professor Jane Endicott Professor Martin Noble
| An Inhibitor's-Eye View of the ATP-Binding Site of CDKs in Different Regulatory States | 2014 |
|
Alex Liu Dr Catherine Drummond Professor Jane Endicott Emeritus Professor Bernard Golding Professor Roger Griffin et al. | An X-ray crystal structure-based understanding of the inhibition of the MDM2-p53 protein-protein interaction by isoindolinones | 2014 |
|
Honorine Lebraud Emeritus Professor Bernard Golding Elisa Meschini Dr Celine Cano Lan Wang et al. | Anticancer agents targeted against cyclin-dependent kinase 2 (CDK2): Structure-based design of irreversible and reversible inhibitors | 2014 |
|
Andrew Shouksmith Laura Evans Professor Roger Griffin Emeritus Professor Bernard Golding Professor Herbie Newell et al. | Design and synthesis of putative small-molecule inhibitors targeting the SCFSKP2 E3 ligase complex | 2014 |
|
Dr Mathew Martin Elisa Meschini Lan Wang Dr Regina Mora Vidal Tristan Reuillon et al. | Identification and characterization of an irreversible inhibitor of CDK2 | 2014 |
|
Dr Alison Hole Dr Sonja Baumli Professor Jane Endicott Professor Martin Noble
| Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity | 2013 |
|
Professor Jane Endicott Professor Martin Noble
| Structural characterization of the cyclin-dependent protein kinase family | 2013 |
|
Professor Martin Noble Professor Jane Endicott
| Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure-Activity Relationship, and Anticancer Activities | 2013 |
|
Professor Jane Endicott Professor Martin Noble
| The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant | 2013 |
|
Professor Martin Noble Professor Jane Endicott
| Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation | 2012 |
|
Professor Jane Endicott
| Synthesis and in Vitro Evaluation of Selective CDK9 Inhibitors | 2012 |
|
Dr Sonja Baumli Dr Alison Hole Professor Martin Noble Professor Jane Endicott
| The CDK9 C-helix Exhibits Conformational Plasticity That May Explain the Selectivity of CAN508 | 2012 |
|
Dr Sonja Baumli Dr Alison Hole Lan Wang Professor Martin Noble Professor Jane Endicott et al. | The CDK9 Tail Determines the Reaction Pathway of Positive Transcription Elongation Factor b | 2012 |
|
Professor Jane Endicott Professor Martin Noble
| The Structural Basis for Control of Eukaryotic Protein Kinases | 2012 |
|
Professor Jane Endicott
| The ubiquitin-associated (UBA) 1 domain of Schizosaccharomyces pombe Rhp23 is essential for the recognition of ubiquitin-proteasome system substrates both in Vitro and in Vivo | 2012 |
|
Dr Ian Hardcastle Alex Liu Dr Eric Valeur Anna Watson Shafiq Ahmed et al. | Isoindolinone Inhibitors of the Murine Double Minute 2 (MDM2)-p53 Protein-Protein Interaction: Structure-Activity Studies Leading to Improved Potency | 2011 |
|
Dr Karim Bennaceur Dr Catherine Drummond Professor Jane Endicott Emeritus Professor Bernard Golding Professor Roger Griffin et al. | MDM2-p53 protein-protein interaction inhibitors: A-ring substituted isoindolinones | 2011 |
|
Professor Martin Noble Dr Ian Hardcastle Professor Jane Endicott
| Understanding small-molecule binding to MDM2: Insights into structural effects of isoindolinone inhibitors from NMR spectroscopy | 2011 |
|
Professor Martin Noble Professor Jane Endicott
| A new crystal form of Lys48-linked diubiquitin | 2010 |
|
Dr Alison Hole Dr Sonja Baumli Professor Jane Endicott
| CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells | 2010 |
|
Elisa Meschini Professor Jane Endicott Emeritus Professor Bernard Golding Dr Ian Hardcastle Professor Herbie Newell et al. | Design and synthesis of dual CDK2 and CDK7 inhibitors | 2010 |
|
Dr Sonja Baumli Professor Jane Endicott
| Halogen Bonds Form the Basis for Selective P-TEFb Inhibition by DRB | 2010 |
|
Professor Jane Endicott Professor Martin Noble
| Recent developments in cyclin-dependent kinase biochemical and structural studies | 2010 |
|
Professor Martin Noble Professor Jane Endicott
| Structure of Rpn10 and Its Interactions with Polyubiquitin Chains and the Proteasome Subunit Rpn12 | 2010 |
|
Professor Jane Endicott Professor Martin Noble
| The structure of CDK4/cyclin D3 has implications for models of CDK activation | 2009 |
|
Professor Jane Endicott Stuart Kemp Dr Lucy Smyth Dr Eric Valeur Emeritus Professor Bernard Golding et al. | Analysis of Chemical Shift Changes Reveals the Binding Modes of Isoindolinone Inhibitors of the MDM2-p53 Interaction | 2008 |
|
Professor Jane Endicott
| CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases | 2008 |
|
Professor Jane Endicott
| Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): Synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex | 2008 |
|
Professor Martin Noble Professor Jane Endicott
| Structures of P. falciparum protein kinase 7 identify an activation motif and leads for inhibitor design | 2008 |
|
Dr Julie Tucker Professor Martin Noble Professor Jane Endicott
| How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A | 2007 |
|
Professor Jane Endicott
| Meriolins, a new class of cell death-inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases | 2007 |
|
Professor Jane Endicott
| Structural biology - Pass the protein | 2007 |
|
Dr Francesco Marchetti Kerry Louise Sayle Dr Johanne Bentley Professor William Clegg Professor Nicola Curtin et al. | Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6- aminopyrimidine inhibitors of cyclin-dependent kinase 2 | 2007 |
|
Dr Johanne Bentley Professor Jane Endicott Professor Martin Noble
| Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity | 2006 |
|
Professor Roger Griffin Andrew Henderson Professor Nicola Curtin Professor Jane Endicott Dr Ian Hardcastle et al. | Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination | 2006 |
|
Professor Jane Endicott Professor Martin Noble
| Structure-based protein kinase inhibitor design | 2006 |
|
Professor Martin Noble Professor Jane Endicott
| Structures of the Dsk2 UBL and UBA domains and their complex | 2006 |
|
Professor Jane Endicott
| Budding yeast Dsk2 protein forms a homodimer via its C-terminal UBA domain | 2005 |
|
Professor Martin Noble Professor Jane Endicott
| Exploiting structural principles to design cyclin-dependent kinase inhibitors | 2005 |
|
Professor Jane Endicott
| Inhibition of the cell cycle with chemical inhibitors: A targeted approach | 2005 |
|
Professor Martin Noble Professor Jane Endicott
| Mechanism of Lys48-linked polyubiquitin chain recognition by the Mud1 UBA domain | 2005 |
|
Professor Martin Noble Professor Jane Endicott
| Molecular basis for the recognition of phosphorylated and phosphoacetylated histone H3 by 14-3-3 | 2005 |
|
Professor Jane Endicott
| Protein kinases as targets for antimalarial intervention: Kinomics, structure-based design, transmission-blockade, and targeting host cell enzymes | 2005 |
|
Dr Ian Hardcastle Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin Professor Jane Endicott et al. | N2-substituted O6-cyclohexylmethylguanine derivatives: Potent inhibitors of cyclin-dependent kinases 1 and 2 | 2004 |
|
Professor Martin Noble Professor Jane Endicott
| Protein kinase inhibitors: Insights into drug design from structure | 2004 |
|
Professor Jane Endicott Professor Martin Noble
| The role of structure in kinase-targeted inhibitor design | 2004 |
|
Dr Veronique Mesguiche Rachel Parsons Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin et al. | 4-Alkoxy-2,6-diaminopyrimidine derivatives: Inhibitors of cyclin dependent kinases 1 and 2 | 2003 |
|
Professor Martin Noble Professor Jane Endicott
| Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects | 2003 |
|
Professor Jane Endicott Professor Martin Noble
| Molecular recognition of indigoids | 2003 |
|
Kerry Louise Sayle Dr Johanne Bentley Professor Alan Calvert Dr YuZhu Cheng Professor Nicola Curtin et al. | Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2 | 2003 |
|
Professor Martin Noble Professor Jane Endicott
| Structures of P-falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition | 2003 |
|
Kerry Louise Sayle Dr Veronique Mesguiche Rachel Parsons Professor Jane Endicott Professor Martin Noble et al. | 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2 | 2002 |
|
Professor Jane Endicott
| Cyclin-dependent kinase homologues of Plasmodium falciparum | 2002 |
|
Dr Ashleigh Gibson Dr Christine Arris Dr Johanne Bentley Professor Nicola Curtin Professor Jane Endicott et al. | Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O6-substituted guanine derivatives | 2002 |
|
Professor Jane Endicott Professor Martin Noble
| Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2 | 2002 |
|
Dr Johanne Bentley Dr Christine Arris Professor Nicola Curtin Professor Jane Endicott Dr Ashleigh Gibson et al. | Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor | 2002 |
|
Professor Jane Endicott Professor Martin Noble
| Structure-based design of cyclin-dependent kinase inhibitors | 2002 |
|
Professor Jane Endicott Professor Martin Noble
| Xenopus phospho-CDK7/cyclin H expressed in baculoviral-infected insect cells | 2001 |
|
Professor Jane Endicott Professor Martin Noble
| Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate | 2001 |
|
Professor Martin Noble Professor Jane Endicott
| Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex | 2000 |
|
Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Professor Jane Endicott Emeritus Professor Bernard Golding et al. | Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles | 2000 |
|
Dr Johanne Bentley Dr Christine Arris Professor Alan Calvert Professor Nicola Curtin Professor Jane Endicott et al. | Structure-activity relationships and cellular effects of novel purine- and pyrimidine-based cyclin dependent kinase inhibitors | 2000 |
|
Professor Martin Noble Professor Jane Endicott
| Chemical inhibitors of cyclin-dependent kinases: Insights into design from X-ray crystallographic studies | 1999 |
|
Professor Jane Endicott Professor Martin Noble Dr Julie Tucker
| Cyclin-dependent kinases: inhibition and substrate recognition | 1999 |
|
Professor Martin Noble Professor Jane Endicott
| Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity | 1999 |
|
Professor Jane Endicott Professor Martin Noble
| Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases | 1999 |
|
Professor Martin Noble Professor Jane Endicott
| Signal transduction proteins: Structural basis of control by phosphorylation | 1999 |
|
Professor Martin Noble Professor Jane Endicott
| The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases | 1999 |
|
Professor Jane Endicott Professor Martin Noble Professor Alan Calvert Professor Nicola Curtin Emeritus Professor Bernard Golding et al. | Insights into CDK inhibitor design from X-ray crystallographic studies | 1998 |
|
Professor Alan Calvert Professor Nicola Curtin Professor Jane Endicott Emeritus Professor Bernard Golding Professor Roger Griffin et al. | O-6-alkylguanines as selective inhibitors of cyclin dependent kinases | 1998 |
|
Professor Jane Endicott Professor Martin Noble
| Structural principles in cell-cycle control: beyond the CDKs | 1998 |
|
Professor Martin Noble Professor Jane Endicott
| Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2 | 1997 |
|
Professor Martin Noble Professor Jane Endicott
| The cyclin box fold: protein recognition in cell-cycle and transcription control | 1997 |
|
Professor Jane Endicott Professor Martin Noble
| The structural basis for control by phosphorylation | 1997 |
|
Professor Jane Endicott Professor Martin Noble
| Crystal structure of the cell cycle-regulatory protein suc1 reveals a beta-hinge conformational switch | 1995 |
|
Professor Jane Endicott
| The cell cycle and suc1: From structure to function? | 1995 |
|
Professor Martin Noble Professor Jane Endicott
| The crystal structure of Cyclin A | 1995 |
|
Professor Jane Endicott Professor Martin Noble
| The crystal structure of p13suc1, a p34cdc2-interacting cell cycle control protein | 1995 |
|
Professor Jane Endicott
| Mutational analysis supports a structural model for the cell cycle protein kinase p34 | 1994 |
|
Professor Jane Endicott
| Characterization of the hemolysin transporter, HlyB, using an epitope insertion | 1992 |
|
Professor Jane Endicott
| Complete cDNA sequences encoding the Chinese hamster P-glycoprotein gene family | 1991 |
|
Professor Jane Endicott
| The Biochemistry of P-Glycoprotein-Mediated Multidrug Resistance | 1989 |
|
Professor Jane Endicott
| Simultaneous expression of two P-glycoprotein genes in drug-sensitive Chinese hamster ovary cells | 1987 |
|
Professor Jane Endicott
| Homology between P-glycoprotein and a bacterial haemolysin transport protein suggests a model for multidrug resistance | 1986 |
|